Evidence map›Paper›PMID 7650486›Full record

ArticleThe Journal of experimental medicine1995

Activation and expression of the nuclear factors of activated T cells, NFATp and NFATc, in human natural killer cells: regulation upon CD16 ligand binding.

J Aramburu, L Azzoni, A Rao, B Perussia

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of experimental medicine, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 2 pooled it
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 2 syntheses or guidelines pooled it, 139 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Unlocking the therapeutic potential of the NFAT pathway in kidney diseases.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. NK Cells: Not Just Followers But Also Initiators of Chronic Vascular Rejection.Transplant international : official journal of the European Society for Organ Transplantation · 2024
    Review
  12. FK506 impairs neutrophil migration that results in increased polymicrobial sepsis susceptibility.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

J AramburuDepartment of Microbiology and Immunology, Jefferson Cancer Institute, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
L Azzoni
A Rao
B Perussia
Thomas Jefferson University · US

Funding

RECEPTORS FOR IMMUNOGLOBULIN G ON LEUKOCYTESR01CA037155 · NCI · WISTAR INSTITUTE · PI PERUSSIA, BICE · 1985 to 1997
–
ACTIVATION OF NON-MHC-RESTRICTED CYTOTOXIC LYMPHOCYTESR01CA045284 · NCI · WISTAR INSTITUTE · PI PERUSSIA, BICE · 1987 to 1998
–
NCI NIH HHS CA37155NCI NIH HHS CA45284
6 · The paper itself

Abstract

The putative factors that couple the signal transduction from surface receptors to the activation of cytokine synthesis in natural killer (NK) cells have not been elucidated. We report here that the nuclear factor of activated T cells (NFATp), a cyclosporin A (CsA)-sensitive factor that regulates the transcription of several cytokines, mediates CD16-induced activation of cytokine genes in human NK cells. CD16 (Fc gamma RIIIA)-induced expression of cytokine mRNA in NK cells occurs via a CsA-sensitive and Ca(2+)-dependent mechanism. Stimulation of NK cells with CD16 ligands induces NFAT-like DNA binding activity in the nuclear extracts from these cells, as detected in electrophoretic mobility shift assays. This occurs with fast kinetics after stimulation, via a CsA-sensitive and Ca(2+)-dependent mechanism that does not require de novo protein synthesis. NK cell NFAT is present in the cytosol of nonstimulated cells, migrates to the nucleus upon stimulation, and can associate with AP-1. Two distinct molecules, NFATp and NFATc, have been reported to mediate NFAT activity. The results of supershift assays using NFATp- and NFATc- specific antibodies indicate that NK cell activation early after CD16 ligand binding involves primarily, if not exclusively, NFATp, and Western blot analysis shows that this has the same electrophoretic mobility (approximately 120 kD) as that of T lymphocytes. NK cells do not express NFATc constitutively, but NFATc mRNA accumulation is induced in these cells within 2 h of stimulation with CD16 ligands. However, supershift assays using the available mAb recognizing the T cell NFATc revealed no detectable NFATc protein in nuclear and cytoplasmic extracts from CD16- or phorbol ester-stimulated cells at any time tested, up to 4 h. These results provide the first direct evidence that both CsA-sensitive transcription factors, NFATp and NFATc, are expressed in human NK cells, and that their activation and/or expression can be regulated in primary cells by a single stimulus, that, in the case of CD16 in NK cells, results in early activation of NFATp and subsequently induced expression of NFATc mRNA.

Indexed as

Nuclear ProteinsAnimalsAntibodies, MonoclonalAntigen-Antibody ComplexBase SequenceB-LymphocytesCell Line, TransformedChlorocebus aethiopsCyclosporineCytokinesDNA-Binding ProteinsGene Expression RegulationHumansInterleukin-12Interleukin-2Killer Cells, NaturalAntibodies, MonoclonalAntigen-Antibody ComplexCyclosporineCytokinesDNA-Binding ProteinsInterleukin-12Interleukin-2LigandsNFATC2 protein, humanNFATC Transcription FactorsNuclear ProteinsReceptors, IgGTranscription Factors

Identifiers

PMID7650486
PMCPMC2192167
OpenAlexW2112278496

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.